Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin in Essential Tremor of the Upper Limb
NCT02207946Phase 2Completed
- Sponsor
- Merz
- Start
- Dec 2014
- Primary completion
- May 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in essential tremor (ET) comparing Xeomin with Placebo (2 arms). Primary endpoint: Change From Baseline to Week 4 in Maximum Angular Tremor Amplitude of the Wrist (Injected Limb). Started Dec 2014; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on NCT02207946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207946.